ARQT
Income statement / Annual
Last year (2023), Arcutis Biotherapeutics, Inc.'s total revenue was $59.61 M,
an increase of 1,517.09% from the previous year.
In 2023, Arcutis Biotherapeutics, Inc.'s net income was -$262.14 M.
See Arcutis Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$59.61 M
|
$3.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$4.99 M |
$754,000.00 |
$763,000.00 |
$455,000.00 |
$195,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
$54.62 M |
$2.93 M |
-$763,000.00 |
-$455,000.00 |
-$195,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.92 |
0.8 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$110.58 M
|
$182.44 M
|
$145.56 M
|
$115.31 M
|
$36.52 M
|
$17.94 M
|
$3.41 M
|
| General & Administrative
Expenses |
$0.00
|
$122.12 M
|
$60.97 M
|
$21.34 M
|
$6.61 M
|
$1.80 M
|
$695,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$185.15 M
|
$122.12 M
|
$60.97 M
|
$21.34 M
|
$6.61 M
|
$1.80 M
|
$695,000.00
|
| Other Expenses |
$0.00 |
$5.82 M |
$173,000.00 |
$967,000.00 |
$1.14 M |
$480,000.00 |
-$872,000.00 |
| Operating Expenses |
$295.72 M |
$304.56 M |
$206.53 M |
$136.65 M |
$43.13 M |
$19.74 M |
$4.11 M |
| Cost And Expenses |
$300.71 M |
$305.31 M |
$206.53 M |
$136.65 M |
$43.13 M |
$19.74 M |
$4.11 M |
| Interest Income |
$0.00 |
$9.83 M |
$173,000.00 |
$967,000.00 |
$1.14 M |
$0.00 |
$0.00 |
| Interest Expense |
$29.71 M |
$15.65 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.88 M
|
$1.25 M
|
$763,000.00
|
$455,000.00
|
$195,000.00
|
$19.74 M
|
$4.11 M
|
| EBITDA |
-$227.43 M
|
-$294.55 M
|
-$205.59 M
|
-$135.22 M
|
-$41.80 M
|
$480,000.00
|
-$872,000.00
|
| EBITDA Ratio |
-3.82 |
-80.25 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-4.04
|
-81.83
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$17.93 M
|
-$9.83 M
|
$173,000.00
|
$967,000.00
|
$1.14 M
|
$480,000.00
|
-$872,000.00
|
| Income Before Tax |
-$259.03 M |
-$311.46 M |
-$206.36 M |
-$135.68 M |
-$42.00 M |
-$19.26 M |
-$4.98 M |
| Income Before Tax Ratio
|
-4.35
|
-84.5
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$3.11 M |
$9.83 M |
-$454,000.00 |
-$84,297.00 |
$23,140.00 |
-$480,000.00 |
-$4.11 M |
| Net Income |
-$262.14 M |
-$321.29 M |
-$205.90 M |
-$135.68 M |
-$42.00 M |
-$19.26 M |
-$4.98 M |
| Net Income Ratio |
-4.4 |
-87.16 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.78 |
-5.84 |
-4.17 |
-3.8 |
-1.1 |
-0.5314 |
-0.1374 |
| EPS Diluted |
-3.78 |
-5.84 |
-4.17 |
-3.8 |
-1.1 |
-0.5314 |
-0.1374 |
| Weighted Average Shares
Out |
$69.31 M
|
$55.03 M
|
$49.41 M
|
$35.67 M
|
$38.09 M
|
$36.24 M
|
$36.24 M
|
| Weighted Average Shares
Out Diluted |
$69.31 M
|
$55.03 M
|
$49.41 M
|
$35.67 M
|
$38.09 M
|
$36.24 M
|
$36.24 M
|
| Link |
|
|
|
|
|
|
|
